Amneal Pharmaceuticals (NASDAQ:AMRX) Updates FY 2025 Earnings Guidance

Amneal Pharmaceuticals (NASDAQ:AMRX) issued an update on its FY 2025 earnings guidance on Friday morning. The company provided EPS guidance of 0.650-0.700 for the period, compared to the consensus EPS estimate of 0.710. The company issued revenue guidance of $3.0 billion-$3.1 billion, compared to the consensus revenue estimate of $2.9 billion.

Wall Street Analysts Forecast Growth

A number of analysts recently commented on the company. StockNews.com downgraded Amneal Pharmaceuticals from a “strong-buy” rating to a “buy” rating in a research report on Thursday, December 19th. JPMorgan Chase & Co. raised Amneal Pharmaceuticals from a “neutral” rating to an “overweight” rating and raised their target price for the company from $9.00 to $12.00 in a research report on Monday. Finally, Piper Sandler boosted their price target on shares of Amneal Pharmaceuticals from $9.00 to $11.00 and gave the stock an “overweight” rating in a report on Monday, November 11th. Six equities research analysts have rated the stock with a buy rating, According to data from MarketBeat.com, the stock currently has a consensus rating of “Buy” and an average target price of $10.60.

Amneal Pharmaceuticals Price Performance

Shares of NASDAQ AMRX opened at $8.38 on Friday. The business’s fifty day moving average price is $8.08 and its 200-day moving average price is $8.31. Amneal Pharmaceuticals has a one year low of $5.01 and a one year high of $9.48. The stock has a market capitalization of $2.60 billion, a PE ratio of -12.32 and a beta of 1.10.

Insiders Place Their Bets

In other news, Director Gautam Patel sold 80,000 shares of the company’s stock in a transaction on Monday, February 3rd. The shares were sold at an average price of $8.14, for a total value of $651,200.00. Following the transaction, the director now owns 1,888,886 shares of the company’s stock, valued at approximately $15,375,532.04. This represents a 4.06 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Insiders have sold a total of 160,000 shares of company stock worth $1,292,000 over the last 90 days. Corporate insiders own 26.56% of the company’s stock.

About Amneal Pharmaceuticals

Amneal Pharmaceuticals, Inc, together with its subsidiaries, develops, manufactures, markets, and distributes generics, injectables, biosimilars, and specialty branded pharmaceutical products worldwide. The company operates through three segments: Generics, Specialty, and AvKARE. The Generics segment offers immediate and extended release oral solid, powder, liquid, sterile injectable, nasal spray, inhalation and respiratory, biosimilar, ophthalmic, film, transdermal patch, and topical products.